<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320940</url>
  </required_header>
  <id_info>
    <org_study_id>MI-5780</org_study_id>
    <nct_id>NCT04320940</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures</brief_title>
  <official_title>A Randomized, Double-Blind, Controlled Study to Assess the Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NEMA Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NEMA Research, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, parallel-group, Phase 3 study to evaluate the efficacy of&#xD;
      the administration of phenobarbital sodium injection in neonates who have suffered from&#xD;
      electrographic or electroclinical seizure. As neonatal seizures can have long-term adverse&#xD;
      effects, including death, placebo-controlled studies are not appropriate for this population.&#xD;
      This study is designed to show intravenous phenobarbital is effective at preventing&#xD;
      subsequent seizures by demonstrating greater efficacy at a higher dose compared to a lower&#xD;
      dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neonates who do not require additional seizure treatment after the first dose of phenobarbital.</measure>
    <time_frame>24 hours</time_frame>
    <description>Percent of neonates who do not require additional seizure treatment after the first dose of phenobarbital during the first 24 hours after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neonates who do not require additional seizure treatment after the first dose of phenobarbital.</measure>
    <time_frame>2 hours</time_frame>
    <description>Percent of neonates who do not require additional seizure treatment after 2 hours of the first dose of phenobarbital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonates who do not require additional seizure treatment after the second dose of phenobarbital.</measure>
    <time_frame>24 hours</time_frame>
    <description>Percent of neonates who do not require additional seizure treatment after the second dose of phenobarbital within the first 24 hours of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure burden</measure>
    <time_frame>48 hours</time_frame>
    <description>Seizure burden over 48 hours following initial administration of the phenobarbital injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Epilepsy, Benign Neonatal</condition>
  <arm_group>
    <arm_group_label>Phenobarbital Sodium Injection 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 20 mg/kg (first/initial dose) followed by 20 mg/kg (if required).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenobarbital Sodium Injection 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 40 mg/kg (first/initial dose) followed by 10 mg/kg (if required).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenobarbital Sodium Injection</intervention_name>
    <description>The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.</description>
    <arm_group_label>Phenobarbital Sodium Injection 20mg</arm_group_label>
    <arm_group_label>Phenobarbital Sodium Injection 40mg</arm_group_label>
    <other_name>Phenobarbital</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female neonates with a gestational age of ≥ 34 - ≤44 weeks admitted into the&#xD;
             NICU with a high probability of developing seizures (e.g., HIE, stroke, intracerebral&#xD;
             hemorrhage, central nervous system infection)&#xD;
&#xD;
          -  Parental informed consent (in-person or remote consent)&#xD;
&#xD;
          -  Undergoing continuous video electroencephalogram (cvEEG) monitoring&#xD;
&#xD;
          -  Has evidence of electrographic seizure burden of at least 30 seconds/h&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received anticonvulsant treatment, including phenobarbital, prior to randomization&#xD;
             (with exception of lorazepam administered for sedation &gt; 24 hours before enrollment)&#xD;
&#xD;
          -  Strong suspicion or confirmed diagnosis of brain malformation, inborn error of&#xD;
             metabolism genetic syndrome, or major congenial malformation prior to randomization&#xD;
&#xD;
          -  Seizures responding to correction of hypoglycemia, hypocalcemia or any other metabolic&#xD;
             disorder&#xD;
&#xD;
          -  Death appears to be imminent as assessed by the NICU attending physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>34 Weeks</minimum_age>
    <maximum_age>44 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taeun Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Taylor, PhD</last_name>
    <phone>2399084442</phone>
    <email>rtaylor@nemaresearch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Colucci, PharmD</last_name>
    <email>rcolucci@nemaresearch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonatal Seizures</keyword>
  <keyword>Phenobarbital</keyword>
  <keyword>Anticonvulsants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsy, Benign Neonatal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenobarbital</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

